Ultima OPCAB System, Sterile, Rx Only, Product Usage: Intended for use during performance of...
FDA Device Recall #Z-0001-2014 — Class II — September 20, 2013
Recall Summary
| Recall Number | Z-0001-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 20, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Maquet Cardiovascular, LLC |
| Location | Wayne, NJ |
| Product Type | Devices |
| Quantity | 20 units (Lot 25052176); 12 units (Lot #25052200) |
Product Description
Ultima OPCAB System, Sterile, Rx Only, Product Usage: Intended for use during performance of minimally invasive cardiac surgery through a sternotomy incision approach. The ULTIMA Access RailPlatform in combination with the Activator II Drive Mechanism is used to spread the sternum, providing access and direct visualization to the thoracic cavity. The AccessRail Platform also allows for the organization of pericardial sutures. The ULTIMA Stablizer isolates and provides local immobilization of the target vessel on the beating heart.
Reason for Recall
MAQUET has identified a potential issue with the ULTIMA OPCAB (part numbers OM-2003S & OM-2001D). Labeling for the 2 blade lots had been incorrectly applied. The standard blades from Lot #25052176 were incorrectly labeled as deep blades, and the 20 deep blades from Lot #25052200 were incorrectly labeled as standard blades.
Distribution Pattern
USA Nationwide Distribution in the states of: Florida, Maryland, New Jersey, New York and Texas.
Lot / Code Information
ULTIMA OPCAB System Part Nos. OM-2003S (LOT #25052176) and OM-2001D (LOT #25052200).
Other Recalls from Maquet Cardiovascular, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2586-2025 | Class II | Heartstring III Proximal Seal System. Intravas... | Aug 15, 2025 |
| Z-2588-2025 | Class II | Heartstring III Proximal Seal System, 4.3 MM. I... | Aug 15, 2025 |
| Z-2587-2025 | Class II | Heartstring III Proximal Seal System, 3.8 MM. I... | Aug 15, 2025 |
| Z-2636-2025 | Class II | Vasoview Hemopro 3 Endoscopic Vessel Harvesting... | Aug 6, 2025 |
| Z-1622-2025 | Class II | The VASOVIEW HEMOPRO 2 Endoscopic Vessel Harves... | Mar 20, 2025 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.